PO.MCB11.01 · 分子与细胞生物学
昼夜节律调节因子PER2缺失通过免疫抑制增强乳腺癌易感性与进展
Lack of circadian regulator PER2 enhances breast cancer susceptibility and progression via immunosuppression
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
昼夜节律(CR)协调着人体几乎所有器官的生理功能。由轮班工作等环境因素或核心时钟基因缺失所导致的昼夜节律紊乱(CRD),与女性生殖系统恶性肿瘤——尤其是乳腺癌(BC)——的易感性升高相关。然而,特定时钟基因的缺陷是否直接赋予乳腺癌易感性并引起全身性免疫抑制,在很大程度上仍未阐明。在此,我们研究了昼夜节律调节因子Period 2(PER2)在乳腺肿瘤发生和免疫逃逸中的作用。
我们整合了来自TCGA数据集的数据,以及在Per2缺陷(Per2 def)和Per2野生型(Per2 wt)小鼠中建立的DMBA诱导乳腺肿瘤模型,通过IHC和流式细胞术评估并分析了肿瘤免疫特征。通过增殖、侵袭和克隆形成实验检测了PER2缺失对乳腺癌恶性程度的影响。机制研究(Western blot、qRT-PCR和荧光素酶实验)界定了PER2依赖性调控肿瘤免疫逃逸的通路。PER2表达在乳腺癌中显著降低,并与女性患者的不良预后相关。Per2^def小鼠对DMBA诱导的乳腺肿瘤形成的易感性显著增加,表明PER2具有内在的肿瘤保护作用。免疫特征分析显示,Per2^def肿瘤呈现出高度免疫抑制的微环境,其特征为细胞毒性CD8⁺ T细胞和CD80⁺ M1型巨噬细胞减少,同时促肿瘤的FOXP3⁺调节性T细胞和CD206⁺ M2型巨噬细胞增多。
在人乳腺癌细胞中,PER2敲低诱导出侵袭性和克隆形成表型,而PER2重建则逆转了这些效应。PER2缺失导致HER2和CD47的表达升高,这两者分别是驱动增殖和免疫逃逸的致癌因子。与此一致,PER2过表达抑制、而PER2沉默增强了HER2和CD47启动子的转录活性。JASPAR预测在两个启动子内均鉴定出CLOCK结合基序,而在MCF7和SKBR3细胞中对这些基序进行突变则显著减弱了转录激活。荧光素酶报告基因实验进一步证明,PER2通过抑制CLOCK介导的反式激活来抑制HER2和CD47的表达。
总之,这些发现揭示PER2缺陷触发CLOCK依赖性的HER2和CD47上调,促进肿瘤侵袭性和免疫逃逸。本研究揭示了时钟基因缺失增强乳腺癌易感性并伴全身性免疫抑制的双重机制,凸显PER2 def-CLOCK-HER2/CD47信号轴作为一个潜在的整合治疗靶点,可用于降低CRD相关的乳腺癌风险和肿瘤侵袭性。
查看英文原文 English abstract
Circadian rhythm (CR) orchestrates the physiological functions of nearly all organs in the human body. Disruption of circadian rhythm (CRD), caused by environmental factors such as shift work or by loss of core clock genes, is associated with heightened susceptibility to malignancies of the female reproductive system, particularly breast cancer (BC). However, whether deficiency of a specific clock gene directly confers breast cancer susceptibility and systemic immune suppression remains largely unresolved. Here, we investigated the role of the circadian regulator Period 2 (PER2) in breast tumorigenesis and immune evasion.
Combined the data from TCGA datasets and a DMBA-induced mammary tumor model established in Per2 def and Per2 wt mice we analyzed the tumor immune profiles assessed by IHC and flow cytometry. The effects of PER2 loss on breast cancer malignancy were tested using proliferation, invasion, and clonogenic assays. Mechanistic studies (Western blot, qRT-PCR, and luciferase assays) defined the PER2-dependent pathway regulating tumor immune escape. PER2 expression was markedly reduced in BC and correlated with poor prognosis in female patients. Per2^def mice exhibited significantly increased susceptibility to DMBA-induced mammary tumor formation, indicating an intrinsic tumor-protective role for PER2. Immune profiling revealed a profoundly immunosuppressed microenvironment in Per2^def tumors, characterized by reduced cytotoxic CD8⁺ T cells and CD80⁺ M1 macrophages, accompanied by elevated pro-tumor FOXP3⁺ regulatory T cells and CD206⁺ M2 macrophages.
In human breast cancer cells, PER2 knockdown induced aggressive and clonogenic phenotypes, whereas PER2 reconstitution reversed these effects. Loss of PER2 led to increased expression of HER2 and CD47, two oncogenic drivers of proliferation and immune evasion, respectively. Consistent with this, PER2 overexpression suppressed, whereas PER2 silencing enhanced, the transcriptional activities of HER2 and CD47 promoters. JASPAR predictions identified CLOCK-binding motifs within both promoters, and mutation of these motifs markedly diminished transcriptional activation in MCF7 and SKBR3 cells. Luciferase reporter assays further demonstrated that PER2 represses HER2 and CD47 expression by inhibiting CLOCK-mediated transactivation.
Collectively, these findings reveal that PER2 deficiency triggers CLOCK-dependent upregulation of HER2 and CD47, promoting both tumor aggressiveness and immune escape. This study uncovers a dual mechanism by which clock gene loss enhances breast cancer susceptibility with systemic immunosuppression, highlighting PER2 def -CLOCK-HER2/CD47 signaling as a potential integrated therapeutic axis to mitigate CRD-associated breast cancer risk and tumor aggressiveness.
利益披露 Disclosure
Y. Duan, None..
H. Zhang, None..
X. Zhang, None..
A. Alexandro, None..
D. Hao, None..
J. Berg, None..
M. Fan, None..
Y. Wang, None..
H. Chen, None..
J. Li, None.